Abstract: Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele. The invention further relates to the use of such recombinant meganucleases in methods for treating retinitis pigmentosa, wherein the mutant RHO P23H allele is preferentially targeted, cleaved, and inactivated.
Type:
Grant
Filed:
February 14, 2020
Date of Patent:
September 1, 2020
Assignee:
Precision BioSciences, Inc.
Inventors:
Victor Bartsevich, Derek Jantz, James Jefferson Smith, Michael G. Nicholson
Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
Abstract: Hydrogel particles and their use in cytometric applications are described. The hydrogel particles described herein are selectively tunable to have at least one optical property substantially similar to the at least one optical property of a target cell. In this regard, the hydrogel particles provided herein in one aspect, are used as a calibration reagent for the detection of a target cell in a sample.
Type:
Grant
Filed:
June 16, 2017
Date of Patent:
August 25, 2020
Assignee:
Slingshot Biosciences, Inc.
Inventors:
Jeffrey Kim, Oliver Liu, Jeremy Agresti, Anh Tuan Nguyen
Abstract: The present disclosure provides nucleic acid molecules encoding an engineered antigen receptor, such as a chimeric antigen receptor or exogenous T cell receptor, and an inhibitory nucleic acid molecule, such as an RNA interference molecule. The present disclosure further relates to nucleic acids, DNA constructs, vectors, pharmaceutical compositions, genetically-modified cells, and methods of treatment that utilize the nucleic acid molecules of the invention.
Abstract: Substituted 1,2,3-triazole compounds are disclosed which have utility in the treatment of a variety of neurological disorders. The compounds provided herein have the general structure: wherein R1, R2, R3 and n are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound provided herein in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for treating neurological disorders in a subject in need thereof.
Type:
Grant
Filed:
October 29, 2018
Date of Patent:
August 11, 2020
Assignee:
Neurocrine Biosciences, Inc.
Inventors:
Neil J. Ashweek, John P. Williams, Deborah Slee, Manisha Moorjani
Abstract: A system, an apparatus, and a method are provided for a modular flow cytometer with a compact size. In one embodiment, the modular flow cytometry system includes the following: a laser system for emitting laser beams; a flow cell assembly positioned to receive the laser beams at an interrogation region of a fluidics stream where fluoresced cells scatter the laser beams into fluorescent light; a fiber assembly positioned to collect the fluorescent light; and a grating system including a dispersive element and a receiver assembly, wherein the dispersive element is positioned to receive the fluorescent light from the fiber assembly and to direct spectrally dispersed light toward the receiver assembly.
Type:
Grant
Filed:
April 26, 2017
Date of Patent:
August 11, 2020
Assignee:
Cytek Biosciences, Inc.
Inventors:
David Vrane, Ming Yan, Eric Chase, Wenbin Jiang
Abstract: The disclosure relates to methods for decreasing feed conversion ratios in fowl through administering isolated microorganisms to the fowl. In particular aspects, the disclosure provides methods of decreasing feed conversion ratios in fowl through administration of a Bacillus sp. to the fowl. The disclosure further relates to isolated microorganisms and compositions comprising the same.
Type:
Application
Filed:
April 20, 2020
Publication date:
August 6, 2020
Applicant:
Ascus Biosciences, Inc.
Inventors:
Mallory EMBREE, Grant GOGUL, Cameron MARTINO, Norm PITT
Abstract: The present invention is directed to methods and compositions for adding tails of specific lengths to a substrate polynucleotide. The invention also contemplates methods and compositions for immobilization of tailed substrates to a solid support. The disclosure contemplates that the attenuator molecule is any biomolecule that associates with a tail sequence added to a substrate polynucleotide and controls the addition of a tail sequence to the 3? end of the substrate polynucleotide. The sequence that is added to the substrate polynucleotide is referred to herein as a tail sequence, or simply a tail, and the process of adding a nucleotide to a substrate polynucleotide is referred to herein as tailing.
Abstract: In accordance with the embodiments herein, a method for displaying differences and similarities between tissue samples utilizing a reference database consisting of tissue images, image analysis features, and derived score from patient tissue samples assayed with a tissue-based test for the purpose of scoring said patient sample and guiding treatment based on said score. The method described herein utilizes digital image analysis of a tissue image of one or more tissue sections to extract features which generates a dataset mathematically representing the image. This dataset is then compared to the reference database to determine reference images with similar and different feature values. Those images are then displayed with the similar and different features highlighted.
Type:
Grant
Filed:
July 31, 2018
Date of Patent:
August 4, 2020
Assignee:
Flagship Biosciences, Inc.
Inventors:
Joseph Krueger, Allison S. Harney, Chris L. Luengo Hendriks
Abstract: Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on a size and type of the tumor to stimulate an immune response against the tumor and other tumors in the subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.
Type:
Grant
Filed:
July 11, 2019
Date of Patent:
August 4, 2020
Assignee:
Pulse Biosciences, Inc.
Inventors:
Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
Abstract: The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within an open reading frame (ORF) of the genome of at least two genotypes of the Hepatitis B virus (HBV). The present invention also encompasses methods of using such engineered meganucleases in a pharmaceutical composition and in methods for treating or reducing the symptoms of a HBV infection, or treating hepatocellular carcinoma (HCC). Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating HBV infections or HCC.
Abstract: This application relates generally to the production of modified, non-natural ?1-?2 domains of NKG2D ligands with attached polypeptides having specific target-binding properties, for example, antibodies or variable fragments of antibodies, that are selectively delivered to Chimeric Antigen Receptors (CARs) comprised of modified, non-natural NKG2D receptors on engineered mammalian cells. The targeting of surface-expressed molecules includes those of virus-infected cells that can then be attacked and ablated by engineered cells of the immunity system expressing CARs cognate to the modified, non-natural ?1-?2 domains of NKG2D ligands with attached polypeptides.
Type:
Application
Filed:
January 28, 2020
Publication date:
July 30, 2020
Applicants:
Xyphos Biosciences Inc., The J. David Gladstone Institutes, A Testamentary Trust Established Under the Will of J. David Glast
Inventors:
Kaman KIM, Nigel KILLEEN, Eytan HERZIG, Warner GREENE
Abstract: The present disclosure provides modified EGFR peptides useful in genetically-modified cells to allow for selection and enrichment of those cells expressing the modified EGFR peptide. For example, isolation of genetically-modified cells expressing a modified EGFR peptide can allow for selection of cells that co-express a chimeric antigen receptor or exogenous T cell receptor. In those instances wherein the genetically-modified cells present adverse effects when administered to a subject, the modified EGFR finds further use as a suicide gene upon administration of an anti-EGFR antibody, leading to depletion of the genetically-modified cells. Also disclosed herein are plasmids and viral vectors comprising a nucleic acid sequence encoding the modified EGFR peptides, and methods of administering compositions comprising the modified EGFR peptides to subjects in order to reduce the symptoms, progression, or occurrence of disease, such as cancer.
Type:
Application
Filed:
October 3, 2018
Publication date:
July 30, 2020
Applicant:
Precision BioSciences, Inc.
Inventors:
Derek Jantz, James Jefferson Smith, Daniel T. MacLeod
Abstract: A method of identifying a therapeutic compound for treating cancer in a human subject, the method including: providing a device that measures cell-substrate impedance; culturing cancer cells in the at least two wells, wherein the cancer cells are obtained from a human subject and have a receptor tyrosine kinase (RTK) pathway; adding to a first well a proposed therapeutic compound that affects an RTK pathway and an RTK stimulating factor for the RTK pathway to form a test well, and adding to another well the RTK stimulating factor to form a control well; continuously monitoring cell-substrate impedance of the at least two wells; and determining a difference in impedance or optionally in cell index between the test well and control well; and if significantly different, concluding the proposed therapeutic compound is therapeutically active in the RTK pathway within the cancer cells of the human subject.
Type:
Grant
Filed:
December 31, 2018
Date of Patent:
July 28, 2020
Assignee:
ACEA Biosciences, Inc.
Inventors:
Yama A. Abassi, Naichen Yu, Josephine Atienza, Xiao Xu, Xiaobo Wang
Abstract: A disposable rapid cell sorter comprises a microfluidic chip with electrodes and sorts biological cells of interest though a magnetic field and an electric field based on biological cell functional antibody bonded magnetic beads and luminescent labeling.
Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
Abstract: Disclosed herein are extracellular vesicles comprising an immunomodulating component. Also provided are methods for producing the extracellular vesicles and methods for using the extracellular vesicles for treating cancer, GvHD, and autoimmune diseases.
Type:
Grant
Filed:
December 28, 2018
Date of Patent:
July 28, 2020
Assignee:
Codiak BioSciences, Inc.
Inventors:
Nuruddeen D. Lewis, Yu Zhou, Sriram Sathyanarayanan, John D. Kulman, Douglas E. Williams, Leonid A. Gaydukov, Ke Xu, Shelly Martin